Clinical Surveillance of Candidemia at Our Hospital

Med Mycol J. 2021;62(2):29-34. doi: 10.3314/mmj.20-00013.

Abstract

Treatment of Candidemia has become increasingly complicated as more and more non-albicans Candida species are being isolated in recent years.We launched an investigation of the species, the MIC value, and the state of administration of antifungal drugs for all the cases with Candida spp. confirmed by blood cultures for the 7-year period from 2012 to 2018 at our hospital. In total, 192 cases were found and 206 strains of Candida species were isolated. Overall, 49.5% of the 206 isolated strains were Candida albicans (102 strains), followed by Candida glabrata (40 strains, 19.4%), and Candida parapsilosis (38 strains, 18.4%). The most frequently used antifungal drug for the initial dose was MCFG (120 cases, 59.2%), while the most frequently switched antifungal agent was L-AMB. Cases with an inappropriate end-of-treatment time represented 58.7% of all the cases.We investigated the Candidemia situation at our hospital for a period of seven years. We believe that it is important for medical institutions to gather detailed data on candidemia at their own hospitals. Likewise, the hospital's Infection Control Team/Antimicrobial Stewardship Team should inform the physicians-in-charge about the appropriate diagnosis and treatment based on the data obtained.

Keywords: candidemia; inappropriate therapy; non-albicans Candida; surveillance.

MeSH terms

  • Antifungal Agents / therapeutic use
  • Candida
  • Candidemia* / drug therapy
  • Candidemia* / epidemiology
  • Hospitals
  • Humans
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents